Table 2.
Demographic, clinical and biological characteristics of the 195 patients from the VErA cohort (group 2)
| Characteristics | Rheumatoid arthritis | Undifferentiated arthritis | Non-RA differentiated arthritis |
|---|---|---|---|
| Number | 116 | 38 | 41 |
| Age in years (mean ± SD (range)) | 52·2 ± 14·5 (24–84) | 50·4 ± 13·4 (19–79) | 51·4 ± 15·1 (23–84) |
| RA duration in months (mean ± SD (range)) | 4·2 ± 1·6 (0·9–6) | 4·5 ± 1·5 (1.5–6) | 4·1 ± 2·1 (1–6) |
| Ritchie index (/78) (mean ± SD (range)) | 10·3 ± 8·9 (0–58) | 5·6 ± 5·1 (0–15) | 6·5 ± 5·3 (0–21) |
| DAS (mean ± SD (range)) | 3·5 ± 1·1 (0·5–7·4) | 2·3 ± 1 (0·6–4·5) | 2·6 ± 0·9 (0·9–4·7) |
| CRP (mg/l) (mean ± SD (range)) | 20·9 ± 27 (2–164) | 13·8 ± 19 (1.5–108) | 17·3 ± 27·5 (3–128) |
| ESR (mm in 1 h) (mean ± SD (range)) | 26·9 ± 23 (2–105) | 17·2 ± 16·5 (2–68) | 24·2 ± 23·5 (2–110) |
| Antibody frequency (%) | |||
| RF-IgG | 38 | 10·5 | 7·3 |
| RF-IgA | 27·6 | 0 | 4·9 |
| RF-IgM | 35·3 | 5·3 | 9·8 |
| Latex test | 28·1 | 5·3 | 2·4 |
| Rose-Waaler test | 27·2 | 2·7 | 5 |
| AKA | 21·6 | 7·9 | 7·3 |
| APF | 37·1 | 10·5 | 7·3 |
| Anti-CCP | 40·5 | 2·6 | 7·3 |
| Anti-GPI | 28·4 | 21·1 | 26·8 |
| Anti-α-enolase | 20·6 | 7·8 | 4·8 |
| Presence of radiological progression (%) | 30·2 | 15·8 | ND |
DAS, Disease Activity Score; RF, rheumatoid factor; AKA, antikeratin antibodies; APF, antiperinuclear factor; ND, not done.